Key points are not available for this paper at this time.
mutations may be promising strategies for synergy with anti-PD-L1 treatments and may help prolong the clinical survival of patients with mUC.
Share your take
Add a clinician perspective alongside expert commentary.
Zeng et al. (2020) studied this question.